Key result
A review of heart failure with preserved ejection fraction discusses the lack of sensitivity and specificity in current diagnostic criteria and the failure of novel treatments to show clinical benefit.
Why the study?
Current diagnostic criteria for HFpEF lack sensitivity and specificity, and pathophysiologically derived novel treatments have not shown clinical or prognostic benefit, prompting an urgent need to revise diagnostic approaches and investigate underlying mechanisms.
This review highlights the urgent need to revise current diagnostic approaches for HFpEF and discusses novel scoring systems like H2PEF and HFA-PEFF alongside treatment perspectives.
Refining HFpEF diagnostics may enable targeted therapies; leaves open which novel approaches succeed in RCTs.
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago. It's accepted that HFpEF is heterogeneous in many ways, ethologically and phenotypically. The underlying mechanisms of the syndrome are not clear. Recently, it has been shown that the diagnostic criteria for HFpEF lacks sensitivity and specificity. Novel treatment approaches, which were developed based on current HFpEF pathophysiological concepts, did not show either clinical or prognostic benefit for patients. Therefore, there is an urgent need to revise current diagnostic approaches and to further investigate the underlying mechanisms. Recently, two novel diagnostic score systems were proposed: H2PEF and HFA-PEFF. Recently, a number of phase II and III randomized control trials have been completed. Here, the authors discuss the potential novel diagnostic approaches to HFpEF and treatment perspectives.
No takes yet. Share an insight, caveat, or question.
Shchendrygina et al. (2021) conducted a review in Heart failure with preserved ejection fraction (HFpEF). A review of heart failure with preserved ejection fraction discusses the lack of sensitivity and specificity in current diagnostic criteria and the failure of novel treatments to show clinical benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: